About this episode

This episode features a discussion on menin inhibitors in acute myeloid leukemia with Dr. Eytan Stein.

In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022 Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6 DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79 AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826 Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutated KOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstract SAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-of KOMET-007…

People in this episode

Hosts: Rajshekhar Chakraborty, Ashwin Kishtagari, Edward Cliff

Guest: Dr. Eytan Stein

Topics covered

• menin inhibitors
• acute myeloid leukemia
• clinical trials
• cancer treatment
• medical research

Keywords

• menin inhibitors
• AML
• clinical trials
• cancer research
• DOT1L inhibitor
• revumenib
• KOMET-001
• AUGMENT-101
• MEN1 mutations

Mentioned in this episode

Organizations: MSKCC

Books & works: ELN 2022 AML Classification, Predictors of outcomes in adults with AML and KMT2A rearrangements, DOT1L inhibitor, AUGMENT 101, Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study, KOMET-001, SAVE trial, KOMET-007, MEN1 mutations

More episodes of Blood Cancer Talks

• Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez · February 27, 2026 · 57 min
• Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo · January 22, 2026 · 44 min
• Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa · January 2, 2026 · 46 min
• Episode 67. Management of CMV in Hematologic Malignancies · November 23, 2025 · 40 min
• Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza · October 15, 2025 · 52 min
• Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain · September 24, 2025 · 53 min

Explore listener stats, chart rankings, contacts and more on the Blood Cancer Talks podcast page.